Does the media favor PACB or TXG?

In the previous week, 10x Genomics had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 5 mentions for 10x Genomics and 4 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 1.05 beat Pacific Biosciences of California's score of 0.95 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TXG or ILMN?

Illumina has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 12.93 -$43.54M -$0.59 N/A Illumina $4.34B 7.76 $850M $5.36 41.65

Is TXG or ILMN more profitable?

Illumina has a net margin of 18.36% compared to 10x Genomics' net margin of -12.18%. Illumina's return on equity of 29.84% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -12.18% -9.33% -7.30% Illumina 18.36% 29.84% 12.17%

Does the media favor TXG or ILMN?

In the previous week, Illumina had 46 more articles in the media than 10x Genomics. MarketBeat recorded 51 mentions for Illumina and 5 mentions for 10x Genomics. Illumina's average media sentiment score of 1.14 beat 10x Genomics' score of 1.05 indicating that Illumina is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 39 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MTD or TXG?

In the previous week, Mettler-Toledo International had 13 more articles in the media than 10x Genomics. MarketBeat recorded 18 mentions for Mettler-Toledo International and 5 mentions for 10x Genomics. Mettler-Toledo International's average media sentiment score of 1.38 beat 10x Genomics' score of 1.05 indicating that Mettler-Toledo International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 16 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, MEDP or TXG?

Medpace has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.84 $451.12M $17.06 36.34 10x Genomics $642.82M 12.93 -$43.54M -$0.59 N/A

Is MEDP or TXG more profitable?

Medpace has a net margin of 17.67% compared to 10x Genomics' net margin of -12.18%. Medpace's return on equity of 110.15% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% 10x Genomics -12.18% -9.33% -7.30%

Does the media prefer MEDP or TXG?

In the previous week, Medpace had 30 more articles in the media than 10x Genomics. MarketBeat recorded 35 mentions for Medpace and 5 mentions for 10x Genomics. Medpace's average media sentiment score of 1.05 beat 10x Genomics' score of 1.05 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 26 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRL or TXG?

In the previous week, Charles River Laboratories International had 4 more articles in the media than 10x Genomics. MarketBeat recorded 9 mentions for Charles River Laboratories International and 5 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.05 beat Charles River Laboratories International's score of 0.49 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Charles River Laboratories International 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

10x Genomics (TXG) Competitors

$63.80 -1.32 (-2.03%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$63.91 +0.11 (+0.17%)

As of 05:50 AM Eastern

Compare

TXG vs. PACB, ILMN, MTD, MEDP, and CRL

Should you buy 10x Genomics stock or one of its competitors? 10x Genomics's main competitors and comparable companies include Pacific Biosciences of California (PACB), Illumina (ILMN), Mettler-Toledo International (MTD), Medpace (MEDP), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does 10x Genomics compare to Pacific Biosciences of California?

Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Pacific Biosciences of California currently has a consensus price target of $1.83, suggesting a potential upside of 43.23%. 10x Genomics has a consensus price target of $38.31, suggesting a potential downside of 39.96%. Given Pacific Biosciences of California's higher possible upside, equities research analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, 10x Genomics had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 5 mentions for 10x Genomics and 4 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 1.05 beat Pacific Biosciences of California's score of 0.95 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.49	-$546.38M	-$0.43	N/A
10x Genomics	$642.82M	12.93	-$43.54M	-$0.59	N/A

10x Genomics has a net margin of -12.18% compared to Pacific Biosciences of California's net margin of -82.49%. 10x Genomics' return on equity of -9.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
10x Genomics	-12.18%	-9.33%	-7.30%

Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

84.7% of 10x Genomics shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

10x Genomics beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Illumina?

10x Genomics (NASDAQ:TXG) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 2.9% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Illumina had 46 more articles in the media than 10x Genomics. MarketBeat recorded 51 mentions for Illumina and 5 mentions for 10x Genomics. Illumina's average media sentiment score of 1.14 beat 10x Genomics' score of 1.05 indicating that Illumina is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	39 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics presently has a consensus target price of $38.31, indicating a potential downside of 39.96%. Illumina has a consensus target price of $188.40, indicating a potential downside of 15.60%. Given Illumina's stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
Illumina	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Illumina has a net margin of 18.36% compared to 10x Genomics' net margin of -12.18%. Illumina's return on equity of 29.84% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Illumina	18.36%	29.84%	12.17%

10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Illumina has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Illumina has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	12.93	-$43.54M	-$0.59	N/A
Illumina	$4.34B	7.76	$850M	$5.36	41.65

Summary

Illumina beats 10x Genomics on 14 of the 17 factors compared between the two stocks.

How does 10x Genomics compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Mettler-Toledo International had 13 more articles in the media than 10x Genomics. MarketBeat recorded 18 mentions for Mettler-Toledo International and 5 mentions for 10x Genomics. Mettler-Toledo International's average media sentiment score of 1.38 beat 10x Genomics' score of 1.05 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	16 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mettler-Toledo International has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market.

Mettler-Toledo International has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	6.96	$869.19M	$44.43	31.49
10x Genomics	$642.82M	12.93	-$43.54M	-$0.59	N/A

Mettler-Toledo International has a net margin of 21.91% compared to 10x Genomics' net margin of -12.18%. 10x Genomics' return on equity of -9.33% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
10x Genomics	-12.18%	-9.33%	-7.30%

Mettler-Toledo International currently has a consensus target price of $1,461.27, indicating a potential upside of 4.45%. 10x Genomics has a consensus target price of $38.31, indicating a potential downside of 39.96%. Given Mettler-Toledo International's stronger consensus rating and higher possible upside, equities research analysts clearly believe Mettler-Toledo International is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Mettler-Toledo International beats 10x Genomics on 12 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Medpace?

Medpace (NASDAQ:MEDP) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

78.0% of Medpace shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 20.5% of Medpace shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Medpace had 30 more articles in the media than 10x Genomics. MarketBeat recorded 35 mentions for Medpace and 5 mentions for 10x Genomics. Medpace's average media sentiment score of 1.05 beat 10x Genomics' score of 1.05 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	26 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.67% compared to 10x Genomics' net margin of -12.18%. Medpace's return on equity of 110.15% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
10x Genomics	-12.18%	-9.33%	-7.30%

Medpace currently has a consensus target price of $584.18, indicating a potential downside of 5.78%. 10x Genomics has a consensus target price of $38.31, indicating a potential downside of 39.96%. Given Medpace's higher probable upside, research analysts plainly believe Medpace is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

Medpace has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.84	$451.12M	$17.06	36.34
10x Genomics	$642.82M	12.93	-$43.54M	-$0.59	N/A

Summary

Medpace beats 10x Genomics on 11 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Charles River Laboratories International has a net margin of -5.96% compared to 10x Genomics' net margin of -12.18%. Charles River Laboratories International's return on equity of 15.75% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
10x Genomics	-12.18%	-9.33%	-7.30%

10x Genomics has lower revenue, but higher earnings than Charles River Laboratories International. 10x Genomics is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.55	-$144.34M	-$4.85	N/A
10x Genomics	$642.82M	12.93	-$43.54M	-$0.59	N/A

Charles River Laboratories International has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

In the previous week, Charles River Laboratories International had 4 more articles in the media than 10x Genomics. MarketBeat recorded 9 mentions for Charles River Laboratories International and 5 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.05 beat Charles River Laboratories International's score of 0.49 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Charles River Laboratories International presently has a consensus target price of $255.65, suggesting a potential downside of 14.43%. 10x Genomics has a consensus target price of $38.31, suggesting a potential downside of 39.96%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, equities analysts clearly believe Charles River Laboratories International is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Charles River Laboratories International beats 10x Genomics on 10 of the 16 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXG vs. The Competition

Export

Metric	10x Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.48B	$10.24B	$7.36B	$12.81B
Dividend Yield	N/A	1.46%	2.54%	10.78%
P/E Ratio	-108.13	62.61	270.58	24.05
Price / Sales	12.93	110.86	641.01	105.04
Price / Cash	N/A	27.04	29.03	36.89
Price / Book	10.22	5.46	11.21	6.40
Net Income	-$43.54M	$56.67B	$3.46B	$347.95M
7 Day Performance	14.69%	4.36%	1.73%	1.48%
1 Month Performance	37.89%	9.77%	7.33%	5.13%
1 Year Performance	353.45%	25.28%	26.14%	17.00%

10x Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXG 10x Genomics	1.7813 of 5 stars	$63.80 -2.0%	$38.31 -40.0%	+346.2%	$8.48B	$642.82M	N/A	1,240	Positive News Gap Down
PACB Pacific Biosciences of California	2.1884 of 5 stars	$1.21 +5.2%	$1.83 +51.5%	-7.2%	$357.45M	$160.01M	N/A	730	Positive News
ILMN Illumina	2.8276 of 5 stars	$193.13 +1.2%	$188.40 -2.4%	+119.3%	$28.82B	$4.34B	36.03	8,650	Positive News
MTD Mettler-Toledo International	3.4097 of 5 stars	$1,417.73 -0.1%	$1,461.27 +3.1%	+6.0%	$28.43B	$4.03B	31.91	18,100	Positive News
MEDP Medpace	3.5175 of 5 stars	$597.12 +3.2%	$584.18 -2.2%	+33.7%	$16.15B	$2.53B	35.00	6,200	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXG) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Competitors

TXG vs. PACB, ILMN, MTD, MEDP, and CRL

How does 10x Genomics compare to Pacific Biosciences of California?

Summary

How does 10x Genomics compare to Illumina?

Summary

How does 10x Genomics compare to Mettler-Toledo International?

Summary

How does 10x Genomics compare to Medpace?

Summary

How does 10x Genomics compare to Charles River Laboratories International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Competitors

TXG vs. PACB, ILMN, MTD, MEDP, and CRL

How does 10x Genomics compare to Pacific Biosciences of California?

Do analysts prefer PACB or TXG?

Does the media favor PACB or TXG?

Which has stronger earnings and valuation, PACB or TXG?

Is PACB or TXG more profitable?

Which has more volatility & risk, PACB or TXG?

Do insiders & institutionals hold more shares of PACB or TXG?

Summary

How does 10x Genomics compare to Illumina?

Do institutionals & insiders have more ownership in TXG or ILMN?

Does the media favor TXG or ILMN?

Do analysts prefer TXG or ILMN?

Is TXG or ILMN more profitable?

Which has more volatility and risk, TXG or ILMN?

Which has higher earnings and valuation, TXG or ILMN?

Summary

How does 10x Genomics compare to Mettler-Toledo International?

Does the media prefer MTD or TXG?

Which has more volatility & risk, MTD or TXG?

Which has better earnings and valuation, MTD or TXG?

Is MTD or TXG more profitable?

Do analysts prefer MTD or TXG?

Do insiders & institutionals believe in MTD or TXG?

Summary

How does 10x Genomics compare to Medpace?

Which has more risk and volatility, MEDP or TXG?

Do insiders & institutionals believe in MEDP or TXG?

Does the media prefer MEDP or TXG?

Is MEDP or TXG more profitable?

Do analysts recommend MEDP or TXG?

Which has higher earnings and valuation, MEDP or TXG?

Summary

How does 10x Genomics compare to Charles River Laboratories International?

Is CRL or TXG more profitable?

Which has higher earnings & valuation, CRL or TXG?

Which has more volatility and risk, CRL or TXG?

Does the media favor CRL or TXG?

Do institutionals and insiders hold more shares of CRL or TXG?

Do analysts recommend CRL or TXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools